Belite Bio KOL Webinar Discussing Progression of Childhood-onset STGD1 and Relevance of the Tinlarebant 18-month Phase 2 Data
About The Event
Join us for a virtual KOL event with Belite Bio, featuring Michel Michaelides, BSc, MB BS, MD(Res), FRCOphth, FACS (Moorfields Eye Hospital and UCL Institute of Ophthalmology) who will discuss the unmet medical need of adolescent patients suffering from Stargardt Disease (STGD1).
The event will focus on progression of childhood-onset STGD1 and Belite Bio’s Phase 2 study evaluating the safety and efficacy of Tinlarebant (LBS-008) in adolescent STGD1 patients. Tinlarebant is an oral therapy intended to reduce the accumulation of ocular vitamin-A based toxins which have been implicated in the onset and progression of STGD1.Tinlarebant has been granted Fast Track Designation and Rare Pediatric Disease designation in the U.S., and Orphan Drug Designation in the U.S. and Europe for the treatment of STGD1.
A live question and answer session will follow the formal presentations.